Volkow on Psychedelics for Addiction: APA 2026 Notes

TL;DR

• The Director of the National Institute on Drug Abuse (NIDA), Nora Volkow, MD, gave the most-attended session of APA 2026 — a special talk on psychedelics as therapeutics for addiction. The room overflowed.
• Psilocybin combined with therapy may help with alcohol use disorder. In a 2022 randomized trial, the psilocybin group had 9.7% heavy drinking days vs 23.6% in the comparison group — sustained over 32 weeks.
• For smoking cessation, psilocybin was 6x more effective than the nicotine patch in a 2026 Johns Hopkins trial: 40.5% prolonged abstinence vs 10%.
• For cocaine use disorder, a single psilocybin session combined with therapy produced 29% more cocaine-abstinent days than active placebo over 6 months.
• Classic psychedelics work differently from addictive drugs. Volkow emphasized: they target serotonin receptors (not dopamine), don't replace one addiction with another, and aren't themselves addictive in clinical use.
• Access is the next problem. Psilocybin remains Schedule I federally; legal access exists only in Oregon, Colorado, and clinical trials. FDA approval is plausible but not yet on the calendar.

This is part of a series of patient-facing posts translating what was discussed at the American Psychiatric Association's 2026 Annual Meeting in San Francisco.

Why Volkow's talk mattered

Nora Volkow has run NIDA — the federal agency that funds nearly all U.S. addiction research — for over two decades. She has more credibility than nearly anyone in this space to evaluate addiction science. When she takes the main stage at APA and makes a case for psychedelics, the field listens.

The session was so full it had to be broadcast to a second overflow room on another floor. APA attendees standing in hallways watched it on screens. That's notable on its own.

Where psychedelics fit, in plain terms

Addiction treatment in 2026 has two main pharmacological approaches:

1. Replacement / substitution — using a less harmful version of the same kind of drug to reduce craving and withdrawal. Examples: methadone or buprenorphine for opioid use disorder, nicotine patches/gum for smoking.
2. Receptor blockers — drugs that prevent the addictive substance from producing its effects. Examples: naltrexone for alcohol or opioid use disorder.

Both approaches help many people. Both have meaningful limitations. Roughly half of patients with alcohol or opioid use disorder relapse within a year even with appropriate medication-assisted treatment.

The question Volkow asked: what if the right intervention isn't replacement or blockade, but resetting the brain circuits that drive compulsive use in the first place?

The mechanism in one paragraph

Classic psychedelics — psilocybin, LSD, DMT — work primarily by activating a specific serotonin receptor called 5-HT2A. This is very different from how addictive drugs work. Stimulants like cocaine and amphetamines work primarily through dopamine. Alcohol and opioids work through their own pathways. None of those overlap meaningfully with the 5-HT2A pathway that psychedelics target.

This matters for two reasons:

1. Psychedelics don't produce the kind of compulsive craving that defines addiction. They aren't addictive in the way addictive drugs are addictive.
2. They may help "reset" the dopamine-driven circuits that drive compulsive use — possibly by promoting neuroplasticity (the brain's ability to form new connections) in regions that have been hijacked by chronic substance use.

In Volkow's words from the session: classic psychedelics for SUD "work on neurotransmitter systems unrelated to the drug in question, don't operate through dopaminergic effects, and are not themselves addictive."

The studies Volkow walked through

Alcohol use disorder

Bogenschutz et al., 2022, JAMA Psychiatry

• 95 adults with alcohol dependence
• Randomized to psilocybin (25-40 mg/70 kg) or diphenhydramine (Benadryl) as an active control
• Both groups received the same structured psychotherapy program
• Followed for 32 weeks

Outcome	Psilocybin	Diphenhydramine control
% of days drinking heavily (Weeks 5-36)	9.7%	23.6%

A more than two-fold difference, sustained over the full follow-up period. Effect size: large.

Smoking cessation

Johnson et al., 2026, JAMA Network Open

• 82 adults who smoked cigarettes regularly
• Randomized to either a single high-dose psilocybin session (30 mg/70 kg) or 8-10 weeks of the standard nicotine patch
• Both groups received a 13-week CBT program

Outcome at 6 months	Psilocybin	Nicotine patch
Prolonged abstinence rate	40.5%	10.0%
7-day point prevalence abstinence	52.4%	25.0%
Odds of abstinence	6.12x higher with psilocybin	—

That's a single supervised session producing better long-term smoking outcomes than 8-10 weeks of the most-prescribed nicotine replacement therapy.

Cocaine use disorder

Hendricks et al., 2026, JAMA Network Open

• A single oral dose of psilocybin (25 mg/70 kg) plus manualized psychotherapy
• Active placebo control (diphenhydramine 100 mg)
• 6-month follow-up

Outcome	Psilocybin	Active placebo
Increase in cocaine-abstinent days	+29%	—
Risk of relapse (hazard ratio)	0.28	—
Relapse rate at 6 months	55% (psilocybin)	79% (placebo)

In a substance use disorder that has had no FDA-approved medications for treatment, the effect size here is meaningful.

Cumulative picture

Across alcohol, nicotine, and cocaine — three of the most common addictions in the U.S. — controlled trials are now showing meaningful benefits from a small number of supervised psilocybin sessions combined with structured therapy. Not a small effect. Not a marginal effect. A 2-6x improvement on the most important outcomes.

What was honest about the limitations

Volkow was direct about three open questions:

1. Is the "mystical experience" necessary?

The subjective experience during a psilocybin session — what's sometimes called a "mystical" or "transformative" experience — correlates with how well treatment works. Patients who report a more profound subjective experience tend to have better outcomes.

But it's not clear whether the experience is causally necessary for the brain changes that produce therapeutic benefit, or whether it's simply a marker for receiving an adequate dose.

This matters because researchers are now developing non-hallucinogenic psychedelics — molecules engineered to produce the brain-circuit changes without the trip. If the experience is necessary, those won't work. If it's just a marker, they could massively expand access (since the supervised session requirement is the main scalability bottleneck).

2. The trial design is challenging

Blinding is hard with psychedelics. Patients usually know whether they got the drug because the experience is so distinctive. This means trial results may be inflated by expectation effects — though, like with ketamine for OCD, the size of the effects suggests expectation alone isn't the full explanation.

3. Long-term safety in real-world use is unknown

The clinical trials use carefully screened populations, structured therapeutic settings, and trained facilitators. We don't yet know how the safety profile holds up in less controlled settings, in patients with complex comorbidities, or with repeated long-term use.

The legal reality

Despite the evidence, psilocybin remains a Schedule I controlled substance federally. Legal access in 2026 exists in:

• Oregon: licensed psilocybin service centers (no medical diagnosis required, but no medical/insurance integration either)
• Colorado: similar regulated program, ramping up since 2024
• Clinical trials: ongoing at academic centers nationwide (listed at ClinicalTrials.gov)

FDA approval for psilocybin in the treatment of major depressive disorder is plausible based on results from late-stage trials by Compass Pathways and Usona Institute. Timing is uncertain — possibly 2-4 years from a successful regulatory pathway.

For most patients in most states, psilocybin therapy is not currently a legal clinical option. The treatments closest to "available now" with related mechanisms are:

• Ketamine therapy for depression, anxiety, PTSD — legal, prescription-based, available via at-home telehealth programs
• Ketamine for alcohol use disorder — being studied; some interventional programs offer it off-label
• Spravato (esketamine) for treatment-resistant depression — FDA-approved

If you're struggling with addiction and interested in psychedelic-assisted approaches, the practical near-term options are: (1) clinical trial enrollment, (2) the Oregon or Colorado state programs if you can travel, (3) ketamine therapy via a legitimate medical provider, since ketamine has the strongest available evidence base among legally accessible options.

Recreational use is rising — that's a separate problem

A bigger-picture data point from Volkow's slides: recreational psychedelic use is rising sharply in the U.S.

Age group	12-month hallucinogen use prevalence
19-30 year olds	3.4% (1988) → 8.1% (2022)
35-50 year olds	0.5% (2008) → 2.5% (2022)

A five-fold increase among middle-aged adults. Law enforcement seizures of psilocybin mushrooms have tripled since 2017.

This is happening regardless of regulatory status. Whether the supervised, evidence-based therapeutic protocols can scale to meet the demand — or whether unsupervised use will continue to be the dominant mode — is the question of the next decade.

What this means for patients today

If you're dealing with addiction:

1. The evidence-based approach that's actually accessible today is medication-assisted treatment plus structured therapy. Methadone or buprenorphine for opioids, naltrexone for alcohol, nicotine replacement for smoking. These work for many people and are widely available.
2. If you're not responding to standard treatment, ask your physician about ketamine therapy specifically. The evidence is earlier-stage than for depression but growing — and ketamine is legally available now.
3. If you're considering Oregon or Colorado psilocybin services, do so with eyes open. These programs are legal but operate outside the medical/insurance system. They're best for people who can integrate the experience with their existing mental healthcare, not as a substitute for it.
4. Stay tuned to the research. This is one of the fastest-moving areas of psychiatry, and the landscape will look different in 12-24 months.

References

• Bogenschutz MP et al. JAMA Psychiatry 2022 — Psilocybin-assisted psychotherapy for alcohol use disorder
• Johnson MW et al. JAMA Network Open 2026 — Psilocybin vs nicotine patch for smoking cessation
• Hendricks PS et al. JAMA Network Open 2026 — Psilocybin for cocaine use disorder
• Volkow ND, Gordon JA, Wargo EM. JAMA Psychiatry 2023 — Psychedelics in psychiatry: future directions
• Goodwin GM et al. New England Journal of Medicine 2022 — Single-dose psilocybin for treatment-resistant depression
• Siegel JS et al. Nature 2024 — Psilocybin desynchronizes the human brain

---

Related Articles

• APA 2026 Annual Meeting Recap
• Ketamine for OCD: Stanford Trial
• Why Most People Can't Access Modern Depression Treatments — Yet
• Psilocybin vs Ketamine: Mechanism, Access, and Evidence

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.